Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
1. Introduction Tumor genotyping has become an integral part of identifying actionable, targetable mutations and administering personalized therapy for patients with advanced non-small cell lung cancer (NSCLC). Non-invasive genotyping assays for plasma cell free DNA (cfDNA) have been adopted broadly for care of advanced NSCLC based on data indicating a high positive predictive value for actionable mutations.[1x[1]Aggarwal, C, Thompson, JC, Black, TA et al.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
